Abstract:The DNA exonuclease TREX1 (Three-prime repair exonuclease 1) is critical for preventing autoimmunity in mice and humans by degrading endogenous cytosolic DNA, which otherwise triggers activation of the innate cGAS/STING pathway leading to the production of type I IFNs. Since tumor cells are prone to aberrant cytosolic DNA accumulation, we hypothesized that they are critically dependent on TREX1 activity to limit their immunogenicity. Here we show, that in tumor cells TREX1 indeed restricts the spontaneous activation of the cGAS/STING pathway and the subsequent induction of a type I IFN response. As a result, TREX1 deficiency compromised in vivo tumor growth in mice. This delay depended on a functional immune system, systemic type I IFN signaling, and tumor-intrinsic cGAS expression. Mechanistically, we show that tumor TREX1 loss drove activation of CD8 T cells and NK cells, prevented CD8 T cell exhaustion and remodeled an immunosuppressive myeloid compartment. Consequently, TREX1 deficiency synergized with T cell directed immune checkpoint blockade. Collectively, we conclude that TREX1 is essential to limit tumor immunogenicity, and that targeting this innate immune checkpoint remodels the tumor microenvironment and enhances anti-tumor immunity by itself and in combination with T cell-targeted therapies. Citation Format: Junghyun Lim, Ryan Rodriguez, Katherine Williams, John Silva, Alan Gutierrez, Paul Tyler, Faezzah Baharom, Tao Sun, Eva Lin, Scott Martin, Brandon Kayser, Robert J. Johnston, Ira Mellman, Lélia Delamarre, Nathaniel West, Sören Müller, Yan Qu, Klaus Heger. The exonuclease TREX1 constitutes an innate immune checkpoint limiting cGAS/STING-mediated anti-tumor immunity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl) nr LB361.

cGAS activation in classical dendritic cells causes autoimmunity in TREX1-deficient mice

Activation of cyclic GMP-AMP synthase by self-DNA causes autoimmune diseases

cGAS activation causes lupus-like autoimmune disorders in a TREX1 mutant mouse model

Mutations in the non-catalytic polyproline motif destabilize TREX1 and amplify cGAS-STING signaling

The exonuclease TREX1 constitutes an innate immune checkpoint limiting cGAS/STING-mediated antitumor immunity

cGAS-activated endothelial cell–T cell cross-talk initiates tertiary lymphoid structure formation

Genome Replication Is Associated With Release of Immunogenic DNA Waste

Structural basis of human TREX1 DNA degradation and autoimmune disease

TREX1 as a Novel Immunotherapeutic Target

Adaptive inhibition of CGAS signaling by TREX1

Abstract LB361: The exonuclease TREX1 constitutes an innate immune checkpoint limiting cGAS/STING-mediated anti-tumor immunity

Aicardi–Goutières Syndrome Protein TREX1 Suppresses L1 and Maintains Genome Integrity Through Exonuclease-Independent ORF1p Depletion

Selective inflammation of the tumor microenvironment and invigorated T cell-mediated tumor control upon induced systemic inactivation of TREX1

ER-directed TREX1 limits cGAS activation at micronuclei

DNA-PK deficiency potentiates cGAS-mediated antiviral innate immunity

T‐Rex escaped from the cytosolic park: Re‐thinking the impact of TREX1 exonuclease deficiencies on genomic stability

Transcription-independent regulation of STING activation and innate immune responses by IRF8 in monocytes

Intratumoral TREX1 induction promotes immune evasion by limiting type I interferon

TREX1 inactivation unleashes cancer cell STING-interferon signaling and promotes anti-tumor immunity

Cyclopeptide Inhibitors Target the N‐Terminal Tail of STING and Alleviate Autoinflammation